Malignant perivascular epithelioid cell tumor mimicking jugular foramen schwannoma: A case report and literature review

Noritaka Komunea,*, Shogo Masudaa, Ryuji Yasumatsua, Takahiro Hongoa,b, Rina Jiromarua,b, Satoshi Matsuoc, Osamu Akiyamad, Nana Tsuchihashia, Nozomu Matsumotoa, Hidetaka Yamamotob, Takashi Nakagawaa

a Department of Otorhinolaryngology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan
b Department of Anatomic Pathology, Pathological Sciences, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan
c Department of Neurosurgery, Clinical Research Institute, National Hospital Organization Kyushu Medical Center, Fukuoka, Japan
d Department of Neurosurgery, Juntendo University, Tokyo, Japan

ARTICLE INFO

Keywords:
Oncology
Surgery
Cancer surgery
Neurosurgery
Ear-Nose-Throat
Jugular foramen
PEComa
Skull base tumor

ABSTRACT

Background: Perivascular epithelioid cell tumors (PEComas) of the skull base are extremely rare. Here we report the first description of a malignant PEComa mimicking jugular foramen schwannoma and presenting as Collet-Sicard syndrome, and we review the previous literature on PEComas of the head, neck and skull base.

Case description: A 29-year-old woman presented with hoarseness, dysphagia, vomiting, and headache. She was first diagnosed with Collet-Sicard syndrome caused by thrombosis of the sigmoid and transverse sinuses. She was treated with anticoagulant therapy, and the hoarseness and paralysis of the accessory nerve improved. Later, at age 31, the hoarseness again worsened. At another hospital, enhanced computed tomography revealed a tumor in the jugular foramen extending to the neck and medially displacing the internal carotid artery. She was referred to our hospital for further examination and was diagnosed with jugular foramen schwannoma causing thrombosis of the sinuses. At the one-year follow-up, the tumor had grown rapidly and had started to surround the internal carotid artery. We therefore performed a tissue biopsy of the tumor in the jugular foramen and neck. Based on pathological analysis, we made a definitive diagnosis of malignant PEComa.

Conclusions: It may be extremely challenging to reach an accurate diagnosis of PEComa in the skull-base region, which can cause a delay in treatment initiation. When atypical clinical features for a skull-base tumor are found, we recommend preliminary biopsy to obtain a definitive diagnosis and initiate an appropriate treatment strategy as early as possible.

1. Introduction

In 1992, Bonetti et al. first described the concept of tumors involving perivascular epithelioid cells (PEC) as a distinct entity [1]. The name “PEComa” was later assigned to these tumors, by Zamboni in 1996 [2]. In 2002, the World Health Organization (WHO) recognized the concept of perivascular epithelioid cell tumors as a family of mesenchymal neoplasms [3], which includes angiomyolipoma, lymphangioleiomyomatosis, and clear cell “sugar” tumors. In general, PEComa is recognized as a benign tumor type, but it reportedly can have malignant characteristics.

The site of origin of this tumor is extremely variable; however, the head and neck are rare origin sites [3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27], and PEComas arising from the skull base are even more unusual [18, 23]. In this report, we describe a case with a PEComa located in the jugular foramen. In this region, paraganglioma and schwannoma are common tumors, and meningioma and metastatic tumors are also relatively frequent. Patients with these tumors may present with Collet-Sicard Syndrome, which is a rare condition characterized by unilateral palsy of the lower cranial nerves (CNs) IX, X, XI, and XII.

To our knowledge, we report here the first case of malignant PEComa arising from the jugular foramen. Interestingly, it mimicked jugular foramen schwannoma and resulted in Collet-Sicard syndrome. This made it extremely difficult to confirm the definitive diagnosis.

* Corresponding author.
E-mail address: norikomu007@gmail.com (N. Komune).
2. Case presentation

A 29-year-old woman without the history of oral contraceptives use presented with hoarseness, dysphagia, vomiting, and headache. Later physical examination in our neurology department also revealed paralysis of the right CNs IX to XII. Contrast-enhanced computed tomography (CT) of the head and neck revealed an interruption of flow in the right sigmoid and transverse sinuses, with no apparent tumor on contrast-enhanced CT scan. Coagulation profile including the prothrombin time, activated partial thromboplastin time was normal. She was diagnosed with Collet-Sicard syndrome caused by thrombosis of the sigmoid and transverse sinuses. She was treated with anticoagulant therapy, and the hoarseness and paralysis of the accessory nerve improved, but recanalization of the sigmoid sinus and transverse sinus was not identified. The hoarseness later worsened again, when she was 31 years old. In another hospital, contrast-enhanced CT scan revealed a tumor in the jugular foramen extending into the deep cervical region and medially displacing the internal carotid artery. The patient was referred to our hospital for further examination of this tumor. The tumor was investigated using contrast-enhanced CT and magnetic resonance imaging. It showed hypointensity on T1-weighted MRI and iso-to hyperintensity on T2-weighted MRI. The smooth tumor rim was enhanced on contrast-enhanced MRI. On a contrast-enhanced CT scan, the tumor displayed slightly heterogeneous enhancement. She was diagnosed with jugular foramen schwannoma (Kaye’s Type C) causing thrombosis of the sigmoid and transverse sinuses. No personal or family history of tuberous sclerosis was reported.

At the one-year follow-up, however, her tumor had grown rapidly, and we found that the tumor had started to surround the internal carotid artery (Figure 1). This clinical course was thought to be atypical for a jugular foramen schwannoma. The tumor was investigated using contrast-enhanced CT and magnetic resonance imaging. It showed hypointensity on T1-weighted MRI and iso-to hyperintensity on T2-weighted MRI. The smooth tumor rim was enhanced on contrast-enhanced MRI. On a contrast-enhanced CT scan, the tumor displayed slightly heterogeneous enhancement. She was diagnosed with jugular foramen schwannoma (Kaye’s Type C) causing thrombosis of the sigmoid and transverse sinuses. No personal or family history of tuberous sclerosis was reported.

201X/10/21

201X+1/05/08

201X+1/09/19

Figure 1. Tumor in the jugular foramen extending into the deep cervical region (Type C jugular foramen tumor). The tumor did not exhibit internal flow voids. It exhibited hypointensity on T1-weighted MRI, and iso-to hyperintensity on T2-weighted MRI. Furthermore, contrast-enhanced T1 MRI showed that the tumor rim was clearly enhanced (A). On a contrast-enhanced CT scan, this tumor displayed slightly heterogeneous enhancement. Tumor had grown rapidly (B) and started to surround the internal carotid artery (C).

3. Discussion

PEComas can arise in a variety of anatomic sites. According to our literature review, sites for head and neck PEComas include the nasal cavity [6, 7, 8, 12, 14, 21, 22, 25], scalp [5, 9, 10], neck soft tissue [10], eye [4, 11, 15, 16, 19, 24, 27], oral cavity [14, 20], larynx [6, 17], pharynx [17, 26], face [13], and skull base [18, 23]. PEComas arising from sites in the skull base like the jugular foramen are extremely rare. Our case is the first report of a jugular foramen PEComa mimicking a schwannoma and resulting in the Collet-Sicard syndrome.

Tumors arising from the jugular foramen vary from common tumors, including schwannomas, paragangliomas, meningiomas and metastatic tumors, to rare tumors such as chondrosarcoma and chordoma [28]. Jugular foramen schwannoma and paraganglioma are diagnosed based on the presence of characteristic radiographical features. However, there are no definitive imaging features used to diagnose PEComa, making it difficult to assign a definitive diagnosis without histological examination.

In our case, she was initially diagnosed with the Collet-Sicard syndrome due to the thrombosis of the sigmoid and transverse sinuses, not tumorigenesis. It made the diagnosis process extremely confusing and difficult. As previously reported, the venous thrombosis around the jugular foramen can be caused of the lower cranial nerve paralysis. Several authors reported the paralysis of cranial nerves IX, X, XI, XII was caused by the thrombosis of the sigmoid-jugular complex similar to our case [29, 30, 31]. As well as thrombosis of the jugular foramen, jugular foramen schwannomas can present paralysis of CNs IX to XII. These findings made it difficult to deny the diagnosis of the schwannoma in our case. Because of the similarity in radiological...
findings between the tumor in this case and typical schwannomas, and previous reports on the cranial nerve paralysis caused by the schwannoma [32, 33, 34], our patient was diagnosed with jugular foramen schwannoma [32]. As a result, it was decided that appropriate approach for this case was to wait and scan. However, the growth pattern was atypical for a schwannoma, which led us to biopsy the tumor from the jugular foramen and deep cervical area.

PEComas are mainly composed of clear to eosinophilic epithelioid or spindle cells, or a mixture of both, which grew in nested and fascicular pattern [10]. Immunohistochemically, melanocytic markers, such as

Figure 2. Histological sections revealed a proliferation of epithelioid cells with enlarged nuclei and eosinophilic or focally clear cytoplasm, arranged in sheets or nested patterns with narrow blood vessels (A). The mitotic index was 2/10 HPF. Necrosis was not evident. Immunohistochemically, tissue tumor cells were positive for α-SMA (B), HMB-45 (C), Melan-A (D), and TFE3 (E), but negative for desmin, AE1/AE3, S-100 protein. The MIB-1 labeling index was approximately 5%. The blue arrows indicate vascular invasion highlighted by EVG staining (F).

Figure 3. The tumor filled the sigmoid sinus and could be separated from the medial wall of the sigmoid sinus (A). It also filled the jugular bulb and extended into the inferior petrosal sinus and posterior condylar vein (B).
Table 1. Perivascular epithelioid cell tumor of the head and neck region. Asterisks indicate the cases with malignant potential, based on Folpe’s criteria.

| Case | Year | Author                  | Location          | Sex | Age | Treatment | Histologic Features | Infiltrative Growth | Vascular Invasion | Nuclear Atypia | Mitoses/10HPF | Necrosis | Follow-up | Immunohistochemical Features |
|------|------|-------------------------|-------------------|-----|-----|-----------|---------------------|-------------------|-----------------|---------------|--------------|----------|-----------|--------------------------------|
| 1    | 2001 | SS. Banerjee            | Nasal Cavity      | F   | 39  | Mixed     | NA                  | NA                | NA              | NA            | Very few     | -        | 12 months/ANED | +                  |
| 2*   | 2004 | NL. Lehman              | Skull Base        | F   | 49  | Not Treated, Epi. | NA                  | +                 | -              | -             | 3 per 50 HPF | Spine, Lung met, DOD | +                  |
| 3*   | 2005 | AL. Folpe               | Scalp             | M   | 80  | NA        | Epi.                | NA                | +              | +            | >10 per 50 HPF | Lost to follow-up | NA               | NA                | NA               | NA             | NA               | NA       |
| 4*   | 2005 | N. Komune et al.        | Neck Soft Tissue  | F   | 77  | SR        | Mixed              | NA                | -              | +            | 1 per 50 HPF | 6 months/ANED | NA               | NA                | NA               | NA             | NA               | NA       |
| 5    | 2005 | S. Banerjee             | Nasal Cavity      | F   | 9   | SR        | Epi.                | NA                | NA              | Very few      | 7 months/ANED | +        | -         | +                  |
| 6    | 2005 | NL. Lehman              | Skull Base        | F   | 46  | NA        | Mixed              | -                | -              | -             | 20 months/ANED | +        | +         | +                  |
| 7    | 2008 | R. Guthoff              | Orbit             | F   | 54  | SR        | NA                | NA              | Very few      | -             | 17 months/ANED | +        | +         | -                  |
| 8*   | 2008 | KB. Calder              | Scalp             | M   | 76  | SR        | Epi.                | NA                | -              | +            | 2 per 10HPF | Cervical node met (5 years previously) | +        | +         | -                  |
| 9    | 2009 | N. Komune               | Nasal Cavity      | F   | 79  | NA        | Epi.                | NA                | NA              | NA            | Follow up too short | +        | +         | +                  |
| 10   | 2009 | H. Huai-yin             | Vocal Cord        | F   | 38  | SR        | Epi.                | NA              | no or only mild atypia with low mitotic activity, two cases focally showed moderate atypia and mitotic activity 1-2/HPF | NA               | NA               | NA             | NA               | NA               | NA       |
| 11   | 2009 | AL. Folpe               | Superior Cerebral Vein | M   | 80  | NA        | Epi.                | NA              | Very few      | -             | 13 months/ANED | +        | +         | -                  |
| 12   | 2009 | N. Komune               | Scalp             | F   | 76  | SR        | Epi.                | NA              | -              | +            | 2 per 10HPF | -        | -         | -                  |
| 13   | 2009 | Panelos                 | Nasal Septum      | F   | 50  | SR        | Mixed              | -                | NA              | Very few      | 6 years/ANED | +        | -         | +                  |
| 14   | 2010 | E. Furusato             | Upper Eyelid      | F   | 26  | SR        | Epi.                | NA                | Very few      | -             | 24 months/ANED | +        | -         | +                  |
| 15   | 2010 | N. Komune               | Inferior Cerebral Vein | M   | 7   | SR        | Epi.                | NA              | Very few      | -             | 24 months/ANED | +        | +         | +                  |
| 16   | 2010 | N. Komune               | Cheek             | F   | 32  | SR        | Mixed              | -                | 2 per HPF     | -             | 4 years/ANED | -        | -         | +                  |
| 17   | 2010 | P. Argani               | Scalp             | M   | 80  | NA        | Epi.                | NA              | NA            | NA            | NA           | +        | -         | +                  |
| 18   | 2011 | N. Komune               | Nasal Cavity      | F   | 18  | SR        | Mixed              | -                | 13 months/ANED | +             | +            | -        | +         | +                  |
| 19   | 2011 | Panelos                 | Nasal Septum      | F   | 71  | SR        | Mixed              | -                | -             | NA            | 26 months/ANED | +        | -         | -                  |
| 20   | 2011 | R. Guthoff              | Scalp             | M   | 80  | NA        | Epi.                | NA              | Very few      | -             | 17 months/ANED | +        | +         | -                  |
| 21   | 2011 | N. Komune               | Scalp             | F   | 76  | SR        | Epi.                | NA              | Very few      | -             | 12 months/ANED | +        | -         | NA                 |
| 22   | 2012 | B. Leavers              | Scalp             | M   | 80  | SR        | Mixed              | -                | -             | 13 months/ANED | +        | +         | +                  |
| 23*  | 2012 | S. Gana                 | Nasal Cavity      | F   | 22  | SR        | Mixed              | NA              | NA            | +             | 13 months/ANED | +        | +         | -                  |
| 24   | 2013 | N. Komune               | Nasal Cavity      | F   | 40  | SR        | Mixed              | -                | 5/50HPF       | +             | 7 years/ANED | +        | -         | -                  |
| 25   | 2016 | I. Lubo                 | Intraorbital      | F   | 74  | SR        | Epi.                | NA              | -             | 2/10HPF       | 40 months/ANED | +        | -         | +                  |
| 26   | 2017 | K. Saluja               | Oropharynx        | F   | 28  | mTOR-I    | Epi.                | NA              | -             | Up to 6/10HPF | 6 month/ANED | +        | -         | +                  |
| 27   | 2017 | A. Varan                | Orbit             | M   | 7   | Chemo.    | Epi.                | NA              | -             | 6 month/tumor size stable | +        | -         | -                  |
| 28   | 2017 | MS. Alam                | Orbit             | M   | 5   | Chem.→SR Epi. | NA              | NA            | +             | 24 months/ANED | +        | -         | +                  |
| 29*  | 2017 | MD. Hyrcza              | Sella Turcica     | F   | 45  | SR        | Epi.                | NA              | NA            | Up to 1/10HPF | -        | -         | +                  |
| 30   | 2017 | Goodman                 | Base of Tongue    | M   | 55  | SR        | Epi.                | NA              | 1/10HPF       | -             | 5 months/ANED | +        | -         | +                  |
| 31   | 2017 | S. Banerjee             | Sinus             | F   | 48  | SR        | Epi.                | NA              | >1/10HPF      | 17 months/ANED | +        | +         | -                  |
| 32   | 2017 | R. Guthoff              | Anterior Nasal    | M   | 8   | SR        | Epi.                | NA              | Very few      | -             | 17 months/ANED | +        | +         | -                  |
| 33*  | 2017 | Komune et al.           | Anterior Nasal    | F   | 31  | SR        | Epi.                | +              | 2/10HPF       | +             | +            | -        | -         | +                  |

ANED, alive with no evidence of disease; Chemo., chemotherapy; Epi., epithelial; HPF, high-power field; Met., metastasis; mTOR, mammalian target of rapamycin inhibitor; NA, not available; Reccur., recurrence; RT, radiation therapy; SR, surgical resection.
HMB-45 and Melan-A, and α-SMA are positive, but cytokeratin is typically negative [6, 10]. Although it has been recognized that PEComas do not express S-100 protein, some studies indicate positivity of S-100 protein [10, 17, 21]. Co-expression of melanocytic markers and SMA is considered to be the hallmark of PEComa. Our case met these histopathological and immunohistological features, and ultimately a diagnosis of PEComa was made. Traditionally, PEComas were thought to be benign tumors, but malignant disease courses with local recurrence and distant metastases have been reported [4, 8, 9, 10, 14, 17, 18, 23, 26]. Folpe et al. proposed that tumors with two or more of the following defining features are considered malignant: tumor size >5 cm, infiltrative growth pattern, high nuclear grade and cellularity, mitotic rate >1/50 HPF, necrosis, and vascular invasion [10]. Tumors composed of nuclear pleomorphism or multinucleated giant cells only, or with a size >5 cm, are considered to be of uncertain malignant potential. The tumor in our case showed infiltrative growth, vascular invasion, nuclear atypia, and high mitotic activity (2/10 HPF), and was thus considered to have malignant potential. However, the application of these criteria to all PEComas arising in the head and neck sites remains controversial. Based on Folpe’s criteria, 12 out of 31 previously reported cases were considered to have malignant potential [18, 23]. One of them resulted in lung and spine metastasis, and the patient died from the disease [23].

During the open biopsy on our patient, the tumor was found to be mainly within the jugular bulb and internal jugular vein. This was one of the reasons for its smooth round shape, which made it look similar to jugular foramen schwannoma. Its infiltration into the sigmoid sinus was thought to be the cause of the thrombosis of the sigmoid and transverse sinuses, and it extended into the internal jugular vein, where it acquired the radiological appearance of a schwannoma.

The optimal treatment strategy for perivascular epithelioid cell tumors remains controversial, but surgical resection with adequate surgical margins is thought to offer the best prognosis. Even if the tumor has malignant potential, surgical treatment offers local control, and our literature review supports surgical intervention as the first choice for both benign or malignant PEComas of the head and neck (Table 1). It is not clear whether radiotherapy and chemotherapy are unequivocally indicated, but they may be for tumors with malignant potential or in cases with incomplete resection. For cases of PEComas in the head and neck region, three groups have reported on neoadjuvant or/adjuvant therapy combined with surgery in the treatment of malignant cases. In all three cases, the patients remained alive for 6–24 months after treatment, with no evidence of recurrence [4, 10, 26].

Although the use of mTOR inhibitor therapy remains controversial, mTOR inhibitors have been considered as an option for treatment, based on the involvement of mTOR pathway activation [26], and because conventional PEComa frequently harbor mutation and loss of heterozygosity of tuberous sclerosis complex (TSC) 2 and much more rarely, TSC1. The significance of loss of heterozygosity at TSC1/2 play a role in regulation the rapamycin (mTOR) pathway [35, 36]. Recently, transcription factor E3 (TFE3) rearranged tumors were shown to lack TSC2 inactivating mutations [37]. The rearranged variant of PEComa may be less responsive to mTOR inhibitor [36]. Saluja et al. reported a malignant opharynx PEComa with strong TFE3 protein expression and gene rearrangement. This case was treated with the mTOR inhibitor everolimus for a month, but this treatment was unsuccessful [26], so a combination of Adriamycin and ifosfamide was used for a month. A palliative dose of radiotherapy to the neck was then added, followed by surgery [26]. Six months after surgery, no local recurrence or distant metastasis were noted. Thusly, the most reliable treatment is still surgical removal. It is therefore essential to make a definitive diagnosis of this type of tumor based on pathological findings. If total removal of tumor cannot be achieved, radiation or adjuvant chemotherapy should be considered soon after histopathological examination result is reported.

In summary, it may be extremely challenging to reach an accurate diagnosis of atypical tumors in the skull-base region, which may result in a delay in treatment initiation. The radiological findings in this case were extremely similar to those for jugular foramen schwannoma; however, the clinical course was not typical of schwannoma. Even if a case has radiographical similarity to common tumors, and despite the fact that biopsy of the jugular foramen tumor is often challenging, a biopsy should be considered in cases with atypical clinical courses and features, in order to obtain a definitive diagnosis and initiate an appropriate treatment strategy as early as possible.

Declarations

Author contribution statement

All authors listed have significantly contributed to the investigation, development and writing of this article.

Funding statement

This work was supported by JSPS KAKENHI Grant Number JP 18K16895.

Competing interest statement

The authors declare no conflict of interest.

Additional information

No additional information is available for this paper.

References

[1] F. Bonetti, M. Pea, G. Martignoni, G. Zamboni, PEC and sugar, Am. J. Surg. Pathol. 16 (3) (1992) 307–308.
[2] G. Zamboni, M. Pea, G. Martignoni, et al., Clear cell “sugar” tumor of the pancreas. A novel member of the family of lesions characterized by the presence of perivascular epithelioid cell tumors, Am. J. Surg. Pathol. 20 (6) (1996) 772–730.
[3] A.L. Folpe, Neoplasms with Perivascular Epithelioid Cell Differentiation, PEComas, 2002.
[4] M.S. Alam, B. Mukherjee, S. Krishnakumar, J. Biswas, Malignant perivascular epithelioid cell tumor of the orbit: report of a case and review of literature, Indian J. Ophthalmol. 65 (9) (2017) 889–891.
[5] P. Argani, S. Aulmann, P.B. Ille, et al., A distinctive subset of PEComas harbors TFE3 gene fusions, Am. J. Surg. Pathol. 34 (10) (2010) 1395–1406.
[6] A. Bandhlah, E. Leon Barnes, J.T. Rabban, J.B. McHugh, Perivascular epithelioid cell tumors (PEComas) of the head and neck: report of three cases and review of the literature, Head Neck Pathol. 5 (3) (2011) 233–240.
[7] S.S. Banerjee, B. Eyden, P.W. Trenholme, et al., Monotypic angiomylolipoma of the nasal cavity: a heretofore undescribed occurrence, Int. J. Surg. Pathol. 9 (4) (2001) 309–315.
[8] C. Bocciolini, A. Fornelli, G.P. Casadei, M.G. Cattani, D. DalDio, PEComa of the nasal cavity with worrisome histologic features and benign behavior: a case report, Ann. Otol. Rhinol. Laryngol. 122 (11) (2013) 725–728.
[9] K.B. Calder, S. Schlauer, M.B. Morgan, Malignant perivascular epithelioid cell tumor (PEComa): a case report and literature review of cutaneous/subcutaneous presentations, J. Cutan. Pathol. 35 (5) (2008) 499–503.
[10] A.L. Folpe, T. Mentzel, H.A. Lehr, C. Fisher, B.L. Balzer, S.W. Weiss, Perivascular epithelioid cell tumors (PEComas) of the head and neck: report of two cases with distinct clinical presentations, Hum. Pathol. 41 (5) (2010) 1575–1579.
[11] E. Furusato, J.D. Cameron, R.W. Newsom, et al., Occular perivascular epithelioid cell tumor: report of 2 cases with distinct clinical presentations, Hum. Pathol. 41 (5) (2010) 768–772.
[12] S. Gana, P. Morbini, G. Giourgos, et al., Early onset of a nasal perivascular epithelioid cell neoplasm not related to tuberous sclerosis complex, Acta Otorhinolaryngol. Ital. : organo ufficiale della Societa italiana di ototinolaringoirologia e chirugia cervico-facciale 32 (3) (2012) 198–201.
[13] N. Ghazali, L. Cascarin, P. Norris, A.W. Barrett, K.M. Laverty, Perivascular epithelioid cell tumor (PEComa) of the cheek, Oral Surg. Oral Med. Oral Pathol. Oral Radiol. Endod. 110 (1) (2010) e26–e31.
[14] A.L.M.K. Goodman, C.C. Griffith, PEComa of the head and neck region: diagnostic challenges of a rare tumor with variable immunophenotype and behavior (Abstract), Mod. Pathol. 30 (S2) (2017) 325.
[15] H. Goto, Y. Uusi, T. Nagao, Perivascular epithelioid cell tumor arising from ciliary body treated by local resection, Ocul Oncol Pathol 1 (2) (2015) 88–92.
[16] R. Guthoff, T. Guthoff, H.K. Mueller-Hermelink, J. Sold-Darseff, E. Geissinger, Perivascular epithelioid cell tumor of the orbit, Arch. Ophthalmol. 126 (7) (2008) 1009–1011.

[17] S. Hai-yin, W. Li-xin, S. Lu, G. Ai-tao, Perivascular epithelioid cell tumors of the laryngopharynx: three case reports and literature review, Pathol. Res. Pract. 205 (9) (2009) 595–605.

[18] M.D. Hyrcza, D.A. Winer, M. Shago, et al., TFE3-Expressing perivascular epithelioid cell neoplasm (PEComa) of the sella turcica, Endocr. Pathol. 28 (1) (2017) 22–26.

[19] P. Iyengar, D.D. Deangelis, M. Greenberg, G. Taylor, Perivascular epithelioid cell tumor of the orbit: a case report and review of the literature, Pediatr. Dev. Pathol. 8 (1) (2005) 98–104.

[20] I.G. Koutlas, S.E. Pambuccian, J. Jessurun, J.C. Manivel, R. Gopalakrishnan, Perivascular epithelioid cell tumor of the oral mucosa, Arch. Pathol. Lab Med. 129 (5) (2005) 690–693.

[21] N. Kuroda, M. Goda, D.V. Kazakov, O. Hes, M. Michal, G.H. Lee, Perivascular epithelioid cell tumor of the nasal cavity with TFE3 expression, Pathol. Int. 59 (10) (2009) 769–776.

[22] B. Leavers, P. Earls, R. Harvey, Sinonasal perivascular epithelioid cell tumor: benign or malignant neoplasm? Am J Rhinol Allergy 26 (3) (2012) 213–217.

[23] N.L. Lehman, Malignant PEComa of the skull base, Am. J. Surg. Pathol. 28 (9) (2004) 1220–1232.

[24] L. Lubo, I. Fermin, O. Massarelli, R. Gobbi, P. Cosma Rocca, Perivascular epithelioid cell tumor with intraorbital location: report of a case and review of the literature, Case reports in pathology 2016 (2016), 1936421.

[25] J. Panelos, O. Gallo, L. Scala, A. Franchi, PEComa of the nasal septum, Otolaryngol-Head Neck Surg : off J Am Acad Otolaryngol-Head Neck Surg 141 (4) (2009) 543–544.

[26] K. Sahjoo, J. Thomas, S. Zhang, et al., Malignant perivascular epithelioid cell tumor of the oropharynx with strong TFE3 expression mimicking alveolar soft part sarcoma: a case report and review of the literature, Hum. Pathol. 76 (2018) 149–155.

[27] A. Varan, T. Bayhan, H. Kiratli, et al., An orbital perivascular epithelioid cell tumor in a 7-year-old boy: case report and review of the literature, J AAPOS : off Publ Am Assoc Pediatric Ophthalmol Strabismus 21 (4) (2017) 525–526, e521.

[28] T.J. Vogl, S. Bindas, Differential diagnosis of jugular foramen lesions, Skull Base : official J North Am Skull Base Soc 19 (1) (2009) 3–16.

[29] N. Byju, J. Jose, K. Safiadheen, V.A. Gafoor, P. Jhenderanath, Cerebral venous thrombosis presenting as multiple lower cranial nerve palsies, Indian J. Crit. Care Med. 16 (4) (2012) 213–215.

[30] T.P. Handley, M.S. Miah, S. Majumdar, S.S. Hussain, Collet-sicard syndrome from thrombosis of the sigmoid jugular complex: a case report and review of the literature, Int J Otolaryngol 2010 (2010).

[31] S. Neo, K.E. Lee, Collet-Sicard syndrome: a rare but important presentation of internal jugular vein thrombosis, Pract. Neurol. 17 (1) (2017) 63–65.

[32] V. Verma, M. Singh, A. Gupta, T. Singh, N. Jaiwal, Jugular foramen schwannoma presenting as Collet-Sicard syndrome: a rare entity, J. Indian Acad. Clin. Med. 12 (2011) 227–229.

[33] S.H. Lee, E.S. Lee, C.H. Yoon, H. Shin, C.H. Lee, Collet-Sicard syndrome with hypoglossal nerve schwannoma: a case report, Ann Rehabil Med 41 (6) (2017) 1100–1104.

[34] E. Palacios, Vocal fold paralysis secondary to a jugular foramen schwannoma, Ear Nose Throat J. 86 (10) (2007) 596–598.

[35] Q. Rao, Q. Shen, Q.Y. Xia, et al., PSF/SFPQ is a very common gene fusion partner in TFE3 rearrangement-associated perivascular epithelioid cell tumors (PEComas) and melanotic Xp11 translocation renal cancers: clinicopathologic, immunohistochemical, and molecular characteristics suggesting classification as a distinct entity, Am. J. Surg. Pathol. 39 (9) (2015) 1181–1196.

[36] J.K. Schoolmeeister, L.N. Dao, W.R. Sukov, et al., TFE3 translocation-associated perivascular epithelioid cell neoplasm (PEComa) of the gynecologic tract: morphology, immunophenotype, differential diagnosis, Am. J. Surg. Pathol. 39 (3) (2015) 394–404.

[37] I. Malinowska, D.J. Kwiatkowski, S. Weiss, G. Martignoni, G. Netto, P. Argani, Perivascular epithelioid cell tumors (PEComas) harboring TFE3 gene rearrangements lack the TSC2 alterations characteristic of conventional PEComas: further evidence for a biological distinction, Am. J. Surg. Pathol. 36 (5) (2012) 783–784.